AM

Amedisys IncNASDAQ AMED Stock Report

Last reporting period 30 Sep, 2024

Updated 22 Nov, 2024

Last price

Market cap $B

3.176

Middle

Exchange

XNAS - Nasdaq

AMED Stock Analysis

AM

Avoid

Based on Eyestock quantitative analysis, AMED`s fundamental data and valuation indicate an investment grade of Avoid at the current time.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

44/100

Low score

Upside

To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.

-1.0 %

Overvalued

Market cap $B

3.176

Dividend yield

Shares outstanding

32.551 B

Amedisys, Inc. is a healthcare services company that provides care and support in the home. The Company's operations involve serving patients through its four operating divisions: home health, hospice, personal care, and high acuity care. The home health segment provides healthcare to help its patients recover from surgery or illness, live with chronic diseases and prevent avoidable hospital readmissions. The segment provides care teams that consists of skilled nurses, care for wounds, monitor vital signs and provide a range of other nursing services. The Hospice segment provides comfort and support for customers who are dealing with a terminal illness. The Personal Care segment provides patients with assistance with the essential activities of daily living. Its high acuity care segment delivers the essential elements of inpatient hospital and skilled nursing facility (SNF) care to patients in their homes. The Company owns and operates approximately 532 care centers in 37 states.

View Section: Eyestock Rating